New concepts in breast cancer therapy

被引:8
作者
Snyder, RD [1 ]
机构
[1] St Vincents Hlth, Dept Oncol, Melbourne, Vic, Australia
关键词
breast neoplasm; antineoplastic agents; hormone therapy; chemoprevention;
D O I
10.1111/j.1444-0903.2004.00586.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Breast cancer is a common disease in the community. Its incidence is increasing but its mortality is falling. New therapeutic approaches based on a biological understanding of the disease are being investigated to improve the outcome. These include the areas of chemo-prevention and therapy in the adjuvant and advanced settings, and some derive from a better understanding of the biology of breast cancer. New prognostic indicators are being studied to enable adjuvant chemotherapy to be directed towards those most likely to benefit. Trastuzumab was the first of the new targeted therapies to be introduced into routine practice. Several other agents targeting a variety of receptors and cell pathways, such as the epidermal growth factor receptor, the vascular epithelial growth factors and various intracellular tyrosine kinase mediated pathways, are under investigation. Increasing attention is being placed on evidence-based supportive care, both for control of symptoms such as hot flushes and for psychosocial problems such as anxiety and depression.
引用
收藏
页码:266 / 269
页数:4
相关论文
共 17 条
[1]  
Australian Institute of Health and Welfare, 2002, CANC AUSTR 1999
[2]  
Baum M, 2002, LANCET, V359, P2131
[3]  
CARLSON RW, 2003, AM SOC CLIN ONCOLOGY, P561
[4]   Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial [J].
Castiglione-Gertsch, M ;
O'Neill, A ;
Price, KN ;
Goldhirsch, A ;
Coates, AS ;
Colleoni, M ;
Nasi, ML ;
Bonetti, M ;
Gelber, RD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (24) :1833-1846
[5]   Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].
Citron, ML ;
Berry, DA ;
Cirrincione, C ;
Hudis, C ;
Winer, EP ;
Gradishar, WJ ;
Davidson, NE ;
Martino, S ;
Livingston, R ;
Ingle, JN ;
Perez, EA ;
Carpenter, J ;
Hurd, D ;
Holland, JF ;
Smith, BL ;
Sartor, CI ;
Leung, EH ;
Abrams, J ;
Schilsky, RL ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439
[6]   Overview of the main outcomes in breast-cancer prevention trials [J].
Cuzick, J ;
Powles, T ;
Veronesi, U ;
Forbes, J ;
Edwards, R ;
Ashley, S ;
Boyle, P .
LANCET, 2003, 361 (9354) :296-300
[7]   Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer [J].
Goldhirsch, A ;
Wood, WC ;
Gelber, RD ;
Coates, AS ;
Thürlimann, B ;
Senn, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3357-3365
[8]   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].
Goss, PE ;
Ingle, JN ;
Martino, S ;
Robert, NJ ;
Muss, HB ;
Piccart, MJ ;
Castiglione, M ;
Tu, D ;
Shepherd, LE ;
Pritchard, KI ;
Livingston, RB ;
Davidson, NE ;
Norton, L ;
Perez, EA ;
Abrams, JS ;
Therasse, P ;
Palmer, MJ ;
Pater, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802
[9]  
Greene FL., 2002, AJCC CANC STAGING HD, V6th
[10]  
iSource National Breast Cancer Centre, 2001, CLIN PRACT GUID MAN